RxDoctor Payments DataLook up a doctor →

James Bennett, MD

Interventional Cardiology · Jackson, MSNPI 1760426670

Payments from drug & device makers

$286,014in general payments, 2019–2025

Across 924 payments — averaging $309.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$139K
  • Abbott$67K
  • Johnson & Johnson$28K
  • Astrazeneca UK Limited$17K
  • Medtronic$13K
  • Philips North America LLC$5K
  • plus $16K from 42 others
$5,000in research payments, 2019–2025

Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$5K

What the payments were for

  • Speaking & faculty fees$126,55679%
  • Travel & lodging$13,4688%
  • Food & beverage$20,21013%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$286,014 in reported general payments places this provider in the 90th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$925,002
Medicare patients
1,671
Services billed
30,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban356$280,742
XareltoRivaroxaban243$152,475
EntrestoSacubitril/Valsartan136$109,636
BrilintaTicagrelor192$97,472
Repatha SureclickEvolocumab56$47,328
FarxigaDapagliflozin Propanediol57$39,032
JardianceEmpagliflozin21$12,120
Metoprolol Succinate445$4,943
Amiodarone Hcl88$3,814
ClopidogrelClopidogrel Bisulfate544$3,706
Rosuvastatin Calcium404$3,534
Amlodipine Besylate370$2,198
Atorvastatin Calcium278$1,800
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,534
Nebivolol Hcl12$1,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$280,742356 claims
Johnson & JohnsonXarelto$27,729$152,475243 claims
AstraZenecaBrilinta, Farxiga$139,496$136,504249 claims
NovartisEntresto$1,132$109,636136 claims
Boehringer IngelheimJardiance$623$12,12021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →